FTB Advisors Inc. lessened its position in Celgene Corporation (NASDAQ:CELG) by 13.0% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,626 shares of the biopharmaceutical company’s stock after selling 692 shares during the quarter. FTB Advisors Inc.’s holdings in Celgene were worth $608,000 as of its most recent filing with the SEC.
Other large investors have also recently modified their holdings of the company. Janus Henderson Group PLC lifted its position in Celgene by 4,290.5% in the 2nd quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock worth $1,092,071,000 after buying an additional 8,217,433 shares in the last quarter. BlackRock Inc. lifted its position in Celgene by 5.7% in the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after buying an additional 3,084,227 shares in the last quarter. Oaktop Capital Management II L.P. purchased a new stake in Celgene in the 2nd quarter worth approximately $271,605,000. Vanguard Group Inc. lifted its position in Celgene by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after buying an additional 1,610,056 shares in the last quarter. Finally, Harbour Capital Advisors LLC lifted its position in Celgene by 12,913.6% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,587,271 shares of the biopharmaceutical company’s stock worth $12,222,000 after buying an additional 1,575,074 shares in the last quarter. Institutional investors and hedge funds own 80.17% of the company’s stock.
In related news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the transaction, the director now owns 85,551 shares in the company, valued at $12,110,599.56. The disclosure for this sale can be found here. Company insiders own 0.95% of the company’s stock.
Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The business had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period last year, the business posted $1.58 EPS. Celgene’s revenue was up 10.2% compared to the same quarter last year. equities analysts anticipate that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.
A number of research firms have issued reports on CELG. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $148.32 target price for the company in a research report on Thursday, August 10th. UBS downgraded shares of Celgene from a “strong-buy” rating to a “market perform” rating and set a $160.00 target price for the company. in a research report on Thursday, October 26th. BMO Capital Markets cut their target price on shares of Celgene from $163.00 to $148.00 and set an “outperform” rating for the company in a research report on Friday, October 27th. Jefferies Group reiterated a “buy” rating and issued a $160.00 target price on shares of Celgene in a research report on Friday, September 15th. Finally, BTIG Research reiterated a “neutral” rating on shares of Celgene in a research report on Tuesday, September 5th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $139.57.
TRADEMARK VIOLATION WARNING: “Celgene Corporation (CELG) Shares Sold by FTB Advisors Inc.” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/12/08/celgene-corporation-celg-shares-sold-by-ftb-advisors-inc.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.